Company Encyclopedia
View More
name
Xintian Pharma
002873.SZ
Guiyang Xintian Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of new Chinese patent medicines in China. The company offers products in various dosage forms, including hard capsules, mixtures, granules, gels, tablets, syrups, wines, dews, etc. Its products are used for the treatment of anti-tumor, gynecological, urological system diseases, oral, breast and thyroid, anti-cold, heat clearing, blood tonic, and cardiovascular diseases.
3.159 T
002873.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking173/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE0.65%D
    • Profit Margin0.99%C
    • Gross Margin73.00%A
  • Growth ScoreD
    • Revenue YoY-9.99%D
    • Net Profit YoY-86.14%E
    • Total Assets YoY6.59%B
    • Net Assets YoY20.70%A
  • Cash ScoreC
    • Cash Flow Margin10065.70%A
    • OCF YoY-9.99%D
  • Operating ScoreC
    • Turnover0.37C
  • Debt ScoreB
    • Gearing Ratio39.64%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Xintian Pharma released its performance for the first three quarters, with a net profit attributable to the parent company of 16.1809 million yuan, a year-on-year decrease of 73.47%

    According to the Zhitong Finance APP, Xintian Pharma released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 559 million yuan, a year-on-year decrease of 15.47%. The net profit attributable to shareholders of the listed company was 16.1809 million yuan, a year-on-year decrease of 73.47%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 13.5545 million yuan, a year-on-year decrease of 67.93%

    Zhitong·
    SZ
    002873
    -0.28%
    Zhitong·
    SZ
    002873
    -0.28%

    Xintian Pharma's controlling shareholder, Xintian Zhiyao, plans to reduce its holdings by no more than 7.05 million shares

    According to the Zhitong Finance APP, Xintian Pharma announced that its controlling shareholder Shanghai Xintian Zhiyao Biotechnology Co., Ltd. (referred to as "Xintian Zhiyao") plans to reduce its holdings of the company's shares by no more than 7.05 million shares through block trades and centralized bidding from November 11, 2025, to February 10, 2026, accounting for 2.9962% of the total share capital after excluding shares in the company's repurchase special account

    Zhitong·
    SZ
    002873
    -0.28%
    Zhitong·
    SZ
    002873
    -0.28%

    Xintian Pharma's Controlling Shareholder To Cut Stake

    Guiyang Xintian Pharmaceutical Co Ltd :SAYS CONTROLLING SHAREHOLDER PLANS TO UNLOAD UP TO 3.0% STAKE IN CO BETWEEN NOV 11 2025 AND FEB 10 2026

    Reuters·
    SZ
    002873
    -0.28%
    Reuters·
    SZ
    002873
    -0.28%

    Xintian Pharma: Xinlikang capsules approved to conduct clinical trials for the treatment of cancer-related fatigue

    According to the Zhitong Finance APP, Xintian Pharma announced that the company recently received the "Drug Clinical Trial Approval Notice" for Xinlikang capsules issued by the National Medical Products Administration, approving the clinical trial for "treatment of cancer-related fatigue."

    Zhitong·
    SZ
    002873
    -0.28%
    Zhitong·
    SZ
    002873
    -0.28%

    Xintian Pharma establishes a new company in traditional Chinese medicine health technology

    According to the Qichacha APP, recently, Guizhou Zhongdao Traditional Chinese Medicine Health Technology Co., Ltd. was established with a registered capital of 10 million yuan. Its business scope includes: elderly care services; remote health management services; medical research and experimental development; engineering and technology research and experimental development, etc. Qichacha's equity penetration shows that the company is wholly owned by Xintian Pharma

    Zhitong·
    SZ
    002873
    -0.28%
    Zhitong·
    SZ
    002873
    -0.28%
    © 2025 Longbridge｜Disclaimer